دورية أكاديمية
[Efficacy of donor lymphocyte infusion in patients after different types of allogeneic hematopoietic stem cell transplantation].
| العنوان: | [Efficacy of donor lymphocyte infusion in patients after different types of allogeneic hematopoietic stem cell transplantation]. |
|---|---|
| المؤلفون: | Slesarchuk OA, Babenko EV, Semenova EV, Bondarenko SN, Éstrina MA, Morozova EV, Paina OV, Vavilov VN, Smirnov BI, Zubarovskaia LS, Afanas'ev BV |
| المصدر: | Terapevticheskii arkhiv [Ter Arkh] 2013; Vol. 85 (7), pp. 26-33. |
| نوع المنشور: | English Abstract; Journal Article |
| اللغة: | Russian |
| بيانات الدورية: | Publisher: ZAO 'Konsilium Medikum Country of Publication: Russia (Federation) NLM ID: 2984818R Publication Model: Print Cited Medium: Print ISSN: 0040-3660 (Print) Linking ISSN: 00403660 NLM ISO Abbreviation: Ter Arkh Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <2018- > : Moskva : ZAO 'Konsilium Medikum' Original Publication: Moskva : Izdatelʹstvo Medit︠s︡ina |
| مواضيع طبية MeSH: | Blood Donors*, Hematopoietic Stem Cell Transplantation/*methods , Lymphocyte Transfusion/*methods, Adolescent ; Adult ; Aged ; Child ; Child, Preschool ; Disease-Free Survival ; Female ; Histocompatibility ; Humans ; Infant ; Kaplan-Meier Estimate ; Leukemia/therapy ; Lymphoma/therapy ; Male ; Middle Aged ; Myelodysplastic Syndromes/therapy ; Secondary Prevention ; Transplantation, Homologous ; Treatment Outcome ; Unrelated Donors ; Young Adult |
| مستخلص: | Aim: To evaluate the efficacy of donor lymphocyte infusion (DLI) to prevent and treat recurrences in patients after different types of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Subjects and Methods: Data from 118 patients with malignant blood diseases were analyzed. Allo-HSCTs from HLA-matched related donors (n=49), HLA-matched unrelated donors (n=50), partially HLA-matched unrelated donors (n=2), and haploidentical donors (n=24) were performed. The indications for DLI were underlying disease relapse (59 DLIs), resistant disease course (n=40), minimal residual disease (n=1 6), falling donor chimerism (n=1 5), and recurrence prevention (n=1 3). Results: Therapy response was obtained after 57 (44%) DLls. There were 36 (25%) and 30 (21%) cases of acute and chronic graft-versus-host reactions (GVHR), respectively. The use of DLI from HLA-matched donors, its performance in the periods of D+100 to one year after allo-HSCT, a donor chimerism level of over 90% at the moment of DLI, the administration of the initial DLI dose of below 1.10(6) CD3+/kg, and the development of chronic GVHR after DLI were associated with the highest rate of therapy responses. The overall survival rates of patients with DLI were significantly influenced by factors, such as DLI periods, donor chimerism levels at DLI, and the development of chronic CVHR after DLI. Conclusion: The choice of the optimal dose of cells, the periods of DLI and its preventive administration improve prognosis in patients after allo-HSCT. The occurrence of acute GVHR is affected by the degree of HLA matching and the type of a donor. The development of chronic GVHR after DLI is associated with the highest rate of responses to DLI and higher survival rates. |
| تواريخ الأحداث: | Date Created: 20131022 Date Completed: 20131104 Latest Revision: 20141120 |
| رمز التحديث: | 20231215 |
| PMID: | 24137944 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 0040-3660 |
|---|